The numbers of CD41+ EVs, CD14+ EVs, and CD142+ EVs were statistically higher in the COVID-19 coagulopathy group, thereby supporting our hypothesis of an association between COVID-19 coagulopathy and EVs. Here, CD14 is linked to blood coagulation disease.